Cited by 137Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchMedical Imaging Techniques and Applications

Tau PET Imaging in Neurodegenerative Disorders

Open access
Groot, Colin, Villeneuve, Sylvia, Smith, Ruben, Hansson, Oskar, Ossenkoppele, Rik·2022·Journal of Nuclear Medicine

Abstract

Decontamination of N95 respirators has become critical to alleviate PPE shortages for healthcare workers in the current COVID-19 emergency. The factors that are considered for the effective reuse of these masks are the fit, filter efficiency and decontamination/disinfection level both for SARS-CoV-2, which is the causative virus for COVID-19, and for other organisms of concern in the hospital environment such as Staphylococcus aureus or Clostridium difficile. In its guidance entitled ‘Recommendations for Sponsors Requesting EUAs for Decontamination and Bioburden Reduction Systems for Surgical Masks and Respirators During the Coronavirus Disease 2019 (COVID19) Public Health Emergency’ (May 2020)[1], the FDA recommends a 6-log10 reduction in either the most resistant bacterial spores for the system or in a mycobacterium species to authorize the use of a decontamination method of N95 respirators for single or multiple users. While the goal is primarily inactivation against SARS-CoV-2, testing of decontamination methods against the virus may not always be available. For decontamination methods considered for only single users, the recommendation is a 6-log10 reduction in the infective virus concentration of 3 non-enveloped viruses or in the concentration of two Gram (+) and two Gram (-) bacteria. Based on these recommendations, we explored the efficacy of vaporized H2O2 (VHP) treatment of N95 respirators against surrogate viruses covering a wide range of disinfection resistance for emergency decontamination and reuse to alleviate PPE shortages for healthcare workers in the COVID-19 emergency.

Integrity signals

Registry

Crossref · 10.2967/jnumed.121.263196

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tau PET is approved by the FDA for in vivo assessment of tau in people with AD.

    “Tau PET uses ligands that bind to neurofibrillary tangles. Tau PET is approved by the FDA for the in vivo assessment of tau in people with AD [178].”
  • Tau PET uses ligands that bind to neurofibrillary tangles.

    “Tau PET uses ligands that bind to neurofibrillary tangles. Tau PET is approved by the FDA for the in vivo assessment of tau in people with AD [178].”
  • Several tau PET tracers have been developed, including first-generation (18F-AV1451/flortaucipir, 18F-THK family, 11C-PBB3) and newer tracers (18F-MK6240, 18F-R0948, 18F-PI260, 18F-GTP1, 18F-JNJ-64326067).

    “There are several tau PET tracers that have been developed so far with the initial first generation (18F-AV1451/now licensed for clinical use in US as flortaucipir, 18F-THK family and 11C-PBB3) and the newer tracers 18F-MK6240, 18F-R0948, 18F-PI260, 18F-GTP1, and 18F-JNJ-64326067 [178, 179].”

The citation lists haven’t been fetched yet

References 78 · Cited by 137

Authors
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R.
Affiliations
  • Lund University (SE)
  • Montreal Neurological Institute and Hospital (CA)
Venue
Journal of Nuclear Medicine
Published
2022-06
Volume
63
Issue
Supplement 1
Pages
20S-26S
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W4282016234
Cited by
137
References
78
Citations by year
2026: 33 · 2025: 52 · 2024: 33 · 2023: 15 · 2022: 4
FWCI
16.10
Type
journal article
Language
en
Open access
Locations
  • Journal of Nuclear Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Pfizer
  • Biogen
  • Eisai
  • Genentech
  • Avid Radiopharmaceuticals
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
tau PET imaging, neurodegenerative diseases, tau protein, positron emission tomography, Alzheimer's disease
MeSH terms
Alzheimer Disease, Cross-Sectional Studies, Humans, United States, tau Proteins, Neurodegenerative Diseases, Tauopathies, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review